Data Insights

By Company Name

By Disease Name

By Drug Name

By Themes

Showing 5 results out of 5

Company Profiles

Access comprehensive reports covering all the major players in the pharmaceutical industry

Gain a competitive edge
Enhance your sales strategy
Get forward-looking insights
Support your decision making

Buy Now

Data Insights

Subasumstat by Takeda Pharmaceutical for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval

Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Subasumstat in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)

Data Insights

Subasumstat by Takeda Pharmaceutical for Non-Small Cell Lung Cancer: Likelihood of Approval

Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Subasumstat in Non-Small Cell Lung Cancer

Data Insights

Subasumstat by Takeda Pharmaceutical for Solid Tumor: Likelihood of Approval

Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Subasumstat in Solid Tumor

Data Insights

Subasumstat by Takeda Pharmaceutical for Cervical Cancer: Likelihood of Approval

Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Subasumstat in Cervical Cancer

Data Insights

Subasumstat by Takeda Pharmaceutical for Relapsed Multiple Myeloma: Likelihood of Approval

Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData,...

Sections

Sections

Sections

Sections

Sections

Company Profiles

Subasumstat by Takeda Pharmaceutical for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval

Subasumstat by Takeda Pharmaceutical for Non-Small Cell Lung Cancer: Likelihood of Approval

Subasumstat by Takeda Pharmaceutical for Solid Tumor: Likelihood of Approval

Subasumstat by Takeda Pharmaceutical for Cervical Cancer: Likelihood of Approval

Subasumstat by Takeda Pharmaceutical for Relapsed Multiple Myeloma: Likelihood of Approval